INVIRASE - CAP 200MG DIN 02216965
Status: Cancelled Post Market
Holder: HOFFMANN-LA ROCHE LIMITED
Molecule: SAQUINAVIR (SAQUINAVIR MESYLATE)
Health Canada record
| Active ingredient(s) | SAQUINAVIR (SAQUINAVIR MESYLATE) 200 MG |
|---|---|
| Dosage form | Capsule |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J05AE01 SAQUINAVIR |
| Original market date | 31-Dec-1996 |
| Current status date | 31-Dec-2018 |
| Source | Health Canada DPD |
Establishment licence of the holder
Hoffmann-La Roche Limited — licence 100006, currently licensed, last inspection rating C (2024-06-25).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing SAQUINAVIR (SAQUINAVIR MESYLATE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02279320 | INVIRASE | HOFFMANN-LA ROCHE LIMITED | Tablet | SAQUINAVIR (SAQUINAVIR MESYLATE) 500 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 16150 | 2014-09-18 | Supplement to a New Drug Submission (SNDS) | DOSING RECOMMENDATIONS FOR TREATMENT-NAIVE PATIENTS WHEN INITIATING TREATMENT |
| 4658 | 1996-03-22 | New Drug Submission (NDS) |